$BMRN
BIOMARIN PHARMACEUTICAL INC

2015 Q4 Form 10-Q Financial Statement

#000156459015009051 Filed on November 02, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q4
Revenue $227.9M $208.9M $230.1M
YoY Change -0.96% 18.33% 56.64%
Cost Of Revenue $42.60M $36.72M $38.30M
YoY Change 11.23% 22.72% 55.69%
Gross Profit $185.3M $172.2M $191.7M
YoY Change -3.34% 17.43% 56.75%
Gross Profit Margin 81.31% 82.42% 83.31%
Selling, General & Admin $112.0M $94.04M $103.1M
YoY Change 8.63% 26.06% 45.21%
% of Gross Profit 60.44% 54.62% 53.78%
Research & Development $176.1M $158.7M $142.1M
YoY Change 23.93% 26.28% 46.04%
% of Gross Profit 95.04% 92.18% 74.13%
Depreciation & Amortization $1.900M $12.70M $6.000M
YoY Change -68.33% 13.39% -500.0%
% of Gross Profit 1.03% 7.38% 3.13%
Operating Expenses $296.5M $252.8M $253.5M
YoY Change 16.96% 26.2% 40.52%
Operating Profit -$111.2M -$81.87M -$61.80M
YoY Change 79.94% -830.81% 6.37%
Interest Expense $33.50M $9.447M -$4.300M
YoY Change -879.07% 3.61% -458.33%
% of Operating Profit
Other Income/Expense, Net -$200.0K -$300.0K $300.0K
YoY Change -166.67% 200.0% -50.0%
Pretax Income $93.00M -$90.44M -$65.70M
YoY Change -241.55% -2907.92% 10.61%
Income Tax $24.30M $483.0K $4.100M
% Of Pretax Income 26.13%
Net Earnings $68.60M -$90.93M -$69.80M
YoY Change -198.28% -1321.3% 12.58%
Net Earnings / Revenue 30.1% -43.53% -30.33%
Basic Earnings Per Share -$0.57
Diluted Earnings Per Share $425.6K -$0.60 -$471.0K
COMMON SHARES
Basic Shares Outstanding 161.3M 160.9M 147.5M shares
Diluted Shares Outstanding 161.1M

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $592.6M $618.4M $945.2M
YoY Change -37.3% -7.2% 20.45%
Cash & Equivalents $397.0M $376.3M $875.5M
Short-Term Investments $195.6M $242.1M $69.70M
Other Short-Term Assets $60.38M $115.3M $108.5M
YoY Change -44.36% 104.28% 160.21%
Inventory $271.7M $262.1M $199.5M
Prepaid Expenses $27.96M $73.17M $35.39M
Receivables $165.0M $148.9M $144.5M
Other Receivables $14.10M $12.70M $9.700M
Total Short-Term Assets $1.090B $1.176B $1.398B
YoY Change -22.04% 9.07% 22.88%
LONG-TERM ASSETS
Property, Plant & Equipment $704.2M $604.5M $523.5M
YoY Change 34.51% 24.2% 63.95%
Goodwill $197.0M $202.4M $54.26M
YoY Change 263.15% 273.02% 0.0%
Intangibles $684.0M $920.9M $156.6M
YoY Change 336.84% 475.77% -4.03%
Long-Term Investments $425.7M $514.4M $97.90M
YoY Change 334.83% 14.54% -63.54%
Other Assets $408.6M $60.79M $54.56M
YoY Change 649.02% -1.21% -65.07%
Total Long-Term Assets $2.640B $2.449B $1.078B
YoY Change 144.93% 79.75% -2.61%
TOTAL ASSETS
Total Short-Term Assets $1.090B $1.176B $1.398B
Total Long-Term Assets $2.640B $2.449B $1.078B
Total Assets $3.729B $3.625B $2.475B
YoY Change 50.66% 48.53% 10.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $186.2M $162.9M $32.78M
YoY Change 468.05% 332.22% -11.15%
Accrued Expenses $197.9M $115.4M $98.49M
YoY Change 100.93% 47.83% 68.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $445.5M $390.5M $235.7M
YoY Change 88.96% 89.05% 28.63%
LONG-TERM LIABILITIES
Long-Term Debt $662.3M $667.8M $642.9M
YoY Change 3.02% 1.66% -1.94%
Other Long-Term Liabilities $44.59M $45.85M $30.08M
YoY Change 48.25% 74.61% -9.93%
Total Long-Term Liabilities $44.59M $45.85M $30.08M
YoY Change 48.25% 74.61% -9.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $445.5M $390.5M $235.7M
Total Long-Term Liabilities $44.59M $45.85M $30.08M
Total Liabilities $1.329B $1.332B $947.5M
YoY Change 40.22% 42.94% 4.92%
SHAREHOLDERS EQUITY
Retained Earnings -$1.022B -$1.090B -$849.8M
YoY Change 20.22% 39.77% 18.72%
Common Stock $3.415B $3.372B $2.360B
YoY Change 44.71% 47.95% 14.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.401B $2.293B $1.528B
YoY Change
Total Liabilities & Shareholders Equity $3.729B $3.625B $2.475B
YoY Change 50.66% 48.53% 10.31%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q4
OPERATING ACTIVITIES
Net Income $68.60M -$90.93M -$69.80M
YoY Change -198.28% -1321.3% 12.58%
Depreciation, Depletion And Amortization $1.900M $12.70M $6.000M
YoY Change -68.33% 13.39% -500.0%
Cash From Operating Activities -$65.80M -$2.900M -$25.40M
YoY Change 159.06% -64.2% 182.22%
INVESTING ACTIVITIES
Capital Expenditures -$103.9M -$44.50M -$27.80M
YoY Change 273.74% 80.89% -6.71%
Acquisitions
YoY Change
Other Investing Activities $183.4M -$18.50M $490.5M
YoY Change -62.61% -88.6% -277.2%
Cash From Investing Activities $79.50M -$63.00M $462.7M
YoY Change -82.82% -66.29% -250.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.500M 3.800M 43.00M
YoY Change -77.91% -57.3% -93.9%
NET CHANGE
Cash From Operating Activities -65.80M -2.900M -25.40M
Cash From Investing Activities 79.50M -63.00M 462.7M
Cash From Financing Activities 9.500M 3.800M 43.00M
Net Change In Cash 23.20M -62.10M 480.3M
YoY Change -95.17% -66.63% 23.31%
FREE CASH FLOW
Cash From Operating Activities -$65.80M -$2.900M -$25.40M
Capital Expenditures -$103.9M -$44.50M -$27.80M
Free Cash Flow $38.10M $41.60M $2.400M
YoY Change 1487.5% 152.12% -88.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45853000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
207767000
CY2015Q3 us-gaap Liabilities
Liabilities
1332213000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
2292640000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144472000
CY2015Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
667793000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
162000
CY2015Q3 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
13897000
dei Document Type
DocumentType
10-Q
CY2015Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
80000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
69706000
CY2015Q3 us-gaap Inventory Net
InventoryNet
262100000
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
159771000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
60790000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
66320000
CY2015Q3 us-gaap Assets
Assets
3624853000
CY2015Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
193202000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
490000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
163000
CY2015Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-186000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
875486000
CY2015Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
30880000
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
31203000
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
97856000
us-gaap Revenues
Revenues
519216000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1435000
CY2014Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-74000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-9105000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3221000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-247689000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4224000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7273000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-90926000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
7445000
us-gaap Net Income Loss
NetIncomeLoss
-240416000
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
160886000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159647000
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
CY2014Q4 us-gaap Assets
Assets
2490453000
CY2015Q3 us-gaap Goodwill
Goodwill
202392000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
1175589000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
604513000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
111835000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523516000
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
231844000
dei Trading Symbol
TradingSymbol
BMRN
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
146245000
CY2015Q3 us-gaap Other Assets Current
OtherAssetsCurrent
115330000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q4 us-gaap Goodwill
Goodwill
54258000
dei Entity Registrant Name
EntityRegistrantName
BIOMARIN PHARMACEUTICAL INC
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
296200000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
1432154000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
156578000
CY2015Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
920943000
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
CY2015Q3 us-gaap Short Term Investments
ShortTermInvestments
241984000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376346000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161251715
dei Amendment Flag
AmendmentFlag
false
CY2015Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
148949000
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
353000
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
74604000
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
94044000
CY2014Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-225000
CY2015Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
1301000
CY2014Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
2636000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
11203000
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
131000
CY2015Q3 us-gaap Royalty Revenue
RoyaltyRevenue
1006000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125686000
us-gaap Royalty Revenue
RoyaltyRevenue
7278000
us-gaap Contracts Revenue
ContractsRevenue
849000
CY2015Q3 us-gaap Long Term Investments
LongTermInvestments
514381000
us-gaap Contracts Revenue
ContractsRevenue
1274000
us-gaap Royalty Revenue
RoyaltyRevenue
3008000
us-gaap Revenues
Revenues
661959000
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
290777000
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161226410
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
149000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
1527894000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2490453000
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30077000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2359744000
CY2014Q4 us-gaap Liabilities
Liabilities
962559000
CY2014Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9695000
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161226410
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27466000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-849770000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-81873000
CY2015Q3 us-gaap Interest Expense
InterestExpense
9447000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1344000
CY2014Q4 us-gaap Inventory Net
InventoryNet
199452000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149093647
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
173416000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
510664000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
149093647
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
658102000
CY2014Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
657976000
CY2015Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
94291000
CY2015Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
34874000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
38767000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3895000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
25184000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
390491000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1090186000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3624853000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
235739000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3371377000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
67500000
us-gaap Costs And Expenses
CostsAndExpenses
873980000
us-gaap Costs And Expenses
CostsAndExpenses
553351000
us-gaap Operating Income Loss
OperatingIncomeLoss
-212021000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34135000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-539000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1102000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3050000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80959000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
53559000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Cost Of Revenue
CostOfRevenue
83946000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
458688000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319476000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
288364000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
202388000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17518000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
15041000
us-gaap Cost Of Revenue
CostOfRevenue
109410000
CY2015Q3 us-gaap Revenues
Revenues
208904000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
158713000
CY2014Q3 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
67500000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
165346000
CY2014Q3 us-gaap Revenues
Revenues
176549000
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
36719000
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
29920000
CY2014Q3 us-gaap Royalty Revenue
RoyaltyRevenue
2780000
CY2014Q3 us-gaap Interest Expense
InterestExpense
9118000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98203000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90443000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
483000
CY2015Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-281000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4293000
us-gaap Interest Expense
InterestExpense
28911000
us-gaap Interest Expense
InterestExpense
27445000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
674000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-68000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59131000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5041000
us-gaap Net Income Loss
NetIncomeLoss
-64172000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147016000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145724000
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161134000
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159304000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159647000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145724000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45306000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39905000
us-gaap Paid In Kind Interest
PaidInKindInterest
21243000
us-gaap Paid In Kind Interest
PaidInKindInterest
20305000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-5748000
us-gaap Share Based Compensation
ShareBasedCompensation
55251000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
8893000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
3022000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
12802000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-12373000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
205000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2354000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
11202000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1059000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2136000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3482000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
41114000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
9783000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6708000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
30930000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-116000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-46515000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89295000
bmrn Payment For Escrow Deposit
PaymentForEscrowDeposit
12500000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
261786000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
207476000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
842873000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
448938000
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
67500000
us-gaap Origination Of Notes Receivable From Related Parties
OriginationOfNotesReceivableFromRelatedParties
3326000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
538392000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
3100000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1259149000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-266357000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
51515000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
37635000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-153652000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
123844000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
61980000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
27970000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1391000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
924000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
790000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1616000
us-gaap Share Based Compensation
ShareBasedCompensation
84465000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
14629000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
463000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
16491000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
15101000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-146000
bmrn Payment Of Contingent Consideration Of Acquisitions
PaymentOfContingentConsiderationOfAcquisitions
4691000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2062000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
21968000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7246000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
888257000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
117464000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
752405000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
265293000
us-gaap Depreciation
Depreciation
36400000
CY2014Q3 us-gaap Depreciation
Depreciation
11200000
us-gaap Depreciation
Depreciation
31300000
CY2015Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
3700000
CY2014Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
2600000
CY2015Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
41761000
CY2015Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
137751000
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
114393000
CY2015Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
82588000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
62571000
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) RECENT ACCOUNTING PRONOUNCEMENTS</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Except as described below, there have been no new accounting pronouncements or changes to accounting pronouncements during the nine months ended September 30, 2015, as compared to the recent accounting pronouncements described in Note 4 of the Company&#8217;s Annual Report on Form 10-K for the year-ended December&#160;31, 2014, that are of significance or potential significance to the Company.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. ASU 2015-03, <font style="font-style:italic;">Interest&#8211;Imputation of Interest (Subtopic 835-30)</font>, which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December&#160;15,&#160;2016, which for the Company is January 1, 2017. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company does not expect that the adoption of this standard will have a material impact on the Company&#8217;s results of operations nor will it result in a reclassification of the balance of deferred offering costs at the time of adoption. If the standard were adopted as of September 30, 2015, the reclassification would approximate $12.6 million.&nbsp;&nbsp;</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the FASB deferred the effective date for ASU No. 2014-09 (ASU 2014-09),<font style="font-style:italic;"> Revenue from Contracts with Customers,</font> by one year. ASU 2014-09 will supersede the revenue recognition requirements in<font style="font-style:italic;"> Revenue Recognition (Topic 605)</font> and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December&#160;15, 2017, including interim periods within that reporting period, which for the Company is January&#160;1, 2018. Early adoption is not permitted.&#160;The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. The Company is currently evaluating the potential impact the adoption of ASU 2014-09 will have on its consolidated financial statements and has not yet selected a transition method.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the FASB issued ASU No. 2015-11, <font style="font-style:italic;">Inventory </font>(ASU 2015-11), which requires an entity to measure inventory within the scope at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The effective date for the standard is for fiscal years beginning after December 15, 2016, which for the Company is January 1, 2017. Early adoption is permitted. The new standard is to be applied prospectively. The Company does not expect ASU 2015-11 to have a material impact on its consolidated financial statements. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, the FASB issued ASU No.&#160;2015-16, <font style="font-style:italic;">Simplifying the Accounting for Measurement-Period Adjustments</font> (ASU 2015-16). The amended guidance requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments are effective prospectively for the fiscal years, and the interim reporting periods within those years, beginning on or after December&#160;15, 2015 and early adoption is permitted. The Company is currently evaluating the potential impact the adoption of ASU 2015-16 will have on its consolidated financial statements and has not elected to early adopt ASU 2015-16. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
463000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
205000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-691000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
916205000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
142676000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2544000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-580000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-499140000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-170776000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
568781000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
398005000
us-gaap Interest Paid Net
InterestPaidNet
4979000
us-gaap Interest Paid Net
InterestPaidNet
4759000
us-gaap Income Taxes Paid
IncomeTaxesPaid
15377000
us-gaap Income Taxes Paid
IncomeTaxesPaid
22378000
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
8271000
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
5663000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
11005000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
7989000
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-11386000
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease
-2762000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
8957000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
16482000
us-gaap Escrow Deposit Disbursements Related To Property Acquisition1
EscrowDepositDisbursementsRelatedToPropertyAcquisition1
116500000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) NATURE OF OPERATIONS AND BUSINESS RISKS</p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#8217;s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. The Company&#8217;s approved products are Vimizim (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks, including: the financial performance of Vimizim, Naglazyme, Kuvan, Aldurazyme and Firdapse; the potential need for additional financings; the Company&#8217;s ability to successfully commercialize its approved product candidates; the uncertainty of the Company&#8217;s research and development (R&amp;D) efforts resulting in future successful commercial products; the Company&#8217;s ability to successfully obtain regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry. </p></div>
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) BASIS OF PRESENTATION</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2014 included in the Company&#8217;s Annual Report on Form 10-K.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#160;31, 2015.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated events and transactions subsequent to the balance sheet date. Based on this evaluation, the Company is not aware of any events or transactions that occurred subsequent to the balance sheet date but prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements, except for the transactions disclosed in Note 21.</p></div>
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
888300000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-90926000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7445000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-240416000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64172000
CY2014Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
156000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22123000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24559000
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
756547000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
575000
CY2015Q3 us-gaap Employee Stock Ownership Plan Esop Gain Loss On Transactions In Deferred Shares
EmployeeStockOwnershipPlanESOPGainLossOnTransactionsInDeferredShares
-4980000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-95906000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7601000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-240416000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-64172000
CY2014Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
9275000
CY2014Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
2238000
CY2014Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
642000
CY2014Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
133000
CY2015Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
248000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22008000
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12240000
bmrn Number Of Products Approved
NumberOfProductsApproved
5
CY2015Q3 bmrn Reclassification Of Deferred Offering Costs
ReclassificationOfDeferredOfferingCosts
12600000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9775000
CY2015Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
93.25
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
757000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
756365000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
167830000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
74000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
342000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
167562000
bmrn Number Of Investments In Marketable Equity Securities
NumberOfInvestmentsInMarketableEquitySecurities
2
CY2015Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
21400000
CY2014Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30800000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
16000000
CY2014 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
18300000
CY2015Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
241984000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
69706000
CY2015Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
514381000
CY2014Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1079792000
CY2015Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
20038000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
97856000
CY2014Q4 us-gaap Investments
Investments
30811000
CY2014Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
4513000
CY2015Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
19957000
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
12021000
CY2015Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
9259000
CY2014Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
11763000
CY2015Q3 us-gaap Investments
Investments
21420000
CY2015Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
756365000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
167562000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
148134000
CY2015Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
123732000
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
123365000
CY2015Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
812088000
CY2014Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
74430000
CY2015Q3 bmrn Indefinite Lived Intangible Assets Held For Sale
IndefiniteLivedIntangibleAssetsHeldForSale
35150000
CY2015Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
970970000
CY2014Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
197795000
CY2015Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
50027000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41217000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
869806000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
228889000
CY2015Q3 us-gaap Depreciation
Depreciation
12700000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
22488000
CY2015Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
73171000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35390000
CY2015Q3 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
16396000
CY2014Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
10513000
CY2014Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
46946000
CY2015Q3 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
7346000
CY2014Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
2354000
CY2014Q4 bmrn Convertible Promissory Note Conversion Option
ConvertiblePromissoryNoteConversionOption
2386000
CY2015Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
12606000
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
9733000
CY2015Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
5811000
CY2015Q3 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
3642000
CY2014Q4 us-gaap Derivative Assets Noncurrent
DerivativeAssetsNoncurrent
5387000
CY2015Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
6512000
CY2014Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
6338000
CY2015Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
162926000
CY2014Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
139513000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
62674000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
45479000
CY2015Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
15450000
CY2014Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
12540000
CY2015Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
27357000
CY2014Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
14859000
CY2015Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9886000
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9050000
CY2015Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
6040000
CY2014Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
5479000
CY2015Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
11867000
CY2014Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
4924000
CY2015Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1156370000
CY2015Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
5000
CY2015Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
-2956000
CY2015Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-2956000
CY2015Q3 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
5739000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32461000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5207000
CY2015Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
9000
CY2015Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5216000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
3126000
CY2015Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
5187000
CY2015Q3 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
-2061000
CY2015Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
5819000
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
15900000
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
12000
us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
15000000
CY2014 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
15900000
us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
109000
us-gaap Asset Retirement Obligation Liabilities Incurred
AssetRetirementObligationLiabilitiesIncurred
748000
us-gaap Asset Retirement Obligation Cash Paid To Settle
AssetRetirementObligationCashPaidToSettle
29000
CY2015Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4593000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
718670
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
56.86
CY2015Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28758000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20004000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
8300000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5700000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
41156000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-8158000
CY2015Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
14000
CY2015Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-8172000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
3126000
CY2015Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
5187000
CY2015Q3 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
-2061000
CY2015Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-10233000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
30923000
CY2015Q2 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
8695000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-2951000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7277000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
33984000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
865000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
3036000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-2171000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
14191000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
15084000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
-893000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-3061000
CY2014Q4 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
6518000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
319000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
1098000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
-779000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-779000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
-1035000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
14171000
bmrn Contingent Payments Upon Achievement Of Certain Regulatory And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainRegulatoryAndLicensingMilestones
763000000
CY2015Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
129200000
CY2015Q3 us-gaap Purchase Obligation
PurchaseObligation
58900000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
546000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1938000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1392000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
14191000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
15084000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
-893000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2282000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
15491000
CY2014Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
-3000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
4138000
CY2014Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
4138000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
9768000
CY2014Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax
562000
CY2014Q3 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
10330000
CY2014Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
14465000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
29956000
CY2014Q2 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
5550000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1493000
CY2014Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
1493000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
3521000
CY2014Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
203000
CY2014Q3 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
3724000
CY2014Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
5217000
CY2014Q3 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
10767000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9941000
CY2014Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-3000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2645000
CY2014Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2645000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
6247000
CY2014Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
359000
CY2014Q3 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
6606000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9248000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19189000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
7756000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
-36000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
8580000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
8580000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
14691000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
13656000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
22200000
CY2013Q4 bmrn Accumulated Other Comprehensive Income Loss Tax
AccumulatedOtherComprehensiveIncomeLossTax
2738000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
3106000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
3106000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
5296000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax
-373000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax
4923000
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
8029000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5018000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5474000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5474000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
9395000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-662000
us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
8733000

Files In Submission

Name View Source Status
0001564590-15-009051-index-headers.html Edgar Link pending
0001564590-15-009051-index.html Edgar Link pending
0001564590-15-009051.txt Edgar Link pending
0001564590-15-009051-xbrl.zip Edgar Link pending
bmrn-10q_20150930.htm Edgar Link pending
bmrn-20150930.xml Edgar Link completed
bmrn-20150930.xsd Edgar Link pending
bmrn-20150930_cal.xml Edgar Link unprocessable
bmrn-20150930_def.xml Edgar Link unprocessable
bmrn-20150930_lab.xml Edgar Link unprocessable
bmrn-20150930_pre.xml Edgar Link unprocessable
bmrn-ex102_235.htm Edgar Link pending
bmrn-ex311_6.htm Edgar Link pending
bmrn-ex312_8.htm Edgar Link pending
bmrn-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending